Justin Zamirowski - 27 May 2022 Form 4 Insider Report for Better Therapeutics, Inc.

Role
Chief Commercial Officer
Signature
/s/ Mark Heinen, Attorney-in-Fact
Issuer symbol
BTTX on OTC
Transactions as of
27 May 2022
Net transactions value
+$838
Form type
4
Filing time
01 Jun 2022, 16:47:11 UTC
Previous filing
18 May 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BTTX Common Stock Options Exercise $838 +1,677 +4.8% $0.5000 36,913 27 May 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BTTX Stock Option (Right to Buy) Options Exercise $0 -1,677 -3.7% $0.000000 43,626 27 May 2022 Common Stock 1,677 $0.5000 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Justin Zamirowski is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 The Assumed Option (as defined in the Agreement and Plan of Merger, dated April 6, 2021, as amended, by and among Mountain Crest Acquisition Corp. II, MCAD Merger Sub Inc. and Better Therapeutics, Inc.) vests as to 1/4th of the shares subject to the Assumed Option on July 27, 2021 and the remaining shares vest in 36 equal monthly installments thereafter, provided the Reporting Person continues to have a service relationship with Issuer on each vesting date. The Assumed Option was granted on August 14, 2020.